Corcept Therapeutics Inc.

CORT ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $129.1M $8.1M $-6.4M $-31.4M $-46.0M $-38.0M $-32.4M $-26.0M
Depreciation & Amortization $106.0K $87.0K $155.0K $141.0K $74.0K $27.0K $3.0K $6.0K
Depreciation
Amortization
Stock-Based Compensation $13.4M $7.1M $6.0M $5.2M $5.2M $5.3M $3.4M $2.1M
Net Cash from Operating Activities $60.9M $18.4M $3.1M $-27.4M $-37.1M $-36.0M $-27.4M $-22.3M
Investing Activities
Capital Expenditures $419.0K $194.0K $17.0K $174.0K $127.0K $151.0K $25.0K
Business Acquisitions
Net Cash from Investing Activities $-73.5M $-194.0K $-127.0K $-151.0K $-25.0K
Financing Activities
Dividends Paid
Stock Repurchases $0 $0
Net Cash from Financing Activities $-8.0M $-7.1M $-970.0K $89.6M $42.5M $23.0M
Net Change in Cash $-20.5M $11.1M $16.2M $-30.6M $-38.2M $53.4M $15.1M $711.0K
Free Cash Flow $60.5M $18.2M $3.1M $-27.6M $-37.2M $-36.2M $-27.4M
← Newer Page 2 of 4 Older →